Apontis Pharma Past Earnings Performance

Past criteria checks 0/6

Apontis Pharma's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 9% per year.

Key information

-48.7%

Earnings growth rate

-59.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-9.0%
Return on equity-22.9%
Net Margin-17.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Recent updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Oct 17
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Jun 18
Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

Apr 05
Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Jul 29
Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Revenue & Expenses Breakdown

How Apontis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:APPH Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2441-7180
31 Mar 2439-9190
31 Dec 2337-11210
30 Sep 2342-7210
30 Jun 2346-3210
31 Mar 23510210
31 Dec 22563200
30 Sep 22563190
30 Jun 22564170
31 Mar 22542180
31 Dec 2151-1200
30 Sep 2148-1210
30 Jun 2146-1220
31 Mar 2142-1200
31 Dec 2039-1180
31 Dec 1940-2190
31 Dec 1820080

Quality Earnings: APPH is currently unprofitable.

Growing Profit Margin: APPH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: APPH is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.

Accelerating Growth: Unable to compare APPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: APPH has a negative Return on Equity (-22.86%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies